Featured Editorial

  1. Patenting RNA Therapeutics In The Age Of AI: What Companies Must Get Right Early 7/8/2026

    As AI transforms RNA discovery, companies must rethink inventorship, obviousness, and patent strategy to secure durable intellectual property protection.

  2. Understanding Therapeutic Oligonucleotide Purification By Anion Exchange Chromatography: From Resin Architecture To Process Productivity 7/7/2026

    Explore how anion exchange chromatography improves oligonucleotide purification through smarter resin design, better separation, and scalable manufacturing.

  3. How Targeted Nanoparticles And Circular RNA Are Advancing CAR-T Development 7/2/2026

    To overcome the short duration of therapeutic protein expression associated with mRNA, Sail Biomedicine has developed novel endless RNA constructs. Michael Lam, Ph.D., discusses its delivery mechanisms and an outlook for future applications.

  4. The Future Of RNA Manufacturing: Continuous Processing, AI, And Distributed Production (Pt. 3) 7/2/2026

    Continuous manufacturing, AI, modular facilities, and next-generation RNA platforms are reshaping how therapies are produced, scaled, and delivered worldwide.

  5. Can Oligonucleotide Regulations Keep Up With Manufacturing Innovation? 7/1/2026

    Here in part 2 of my TIDES takeaways, I’ll unpack which guidances we have at our disposal today in the oligo world, and what we can expect in the future. 

  6. Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression 6/29/2026

    While circular RNA platforms can enhance protein expression, developing effective delivery strategies remains the key challenge to achieving therapeutic efficacy.

  7. Unlocking The Future Of mRNA 6/29/2026

    Many regulatory frameworks and analytical approaches were not originally designed for platforms like mRNA. Addressing these gaps will be essential to fully realize the potential of mRNA technologies.

  8. The Missing Partners In microRNA Silencing: What QKI Reveals About RNA Regulatory Complexity 6/26/2026

    New research suggests microRNA silencing depends on RNA-binding protein partners like QKI, revealing a more complex regulatory network shaping gene expression.

  9. The Hidden Bottleneck In Advanced Therapies Isn't Science… It's Translational Friction 6/26/2026

    Scientific breakthroughs may spark innovation, but operational excellence ultimately determines which advanced therapies reach patients.

  10. RNA Therapeutics: Why CMC Strategy Will Define The Next Decade 6/25/2026

    As RNA matures into an industrial platform, long-term success will depend less on discovery and more on scalable CMC systems, integration, and execution.